Business Wire

Secure-IC Acquires Silex Insight’s Security Business to Accelerate Its Chip-to-Cloud Plan and Develop the Next-generation of Embedded Cybersecurity Solutions

Share

Secure-IC, the rising leader, and the unique global provider of end-to-end cybersecurity solutions for embedded systems and connected objects, announces today the acquisition of Silex Insight’s security business. Silex Insight is a leading provider for flexible and scalable security IP cores solutions which perfectly complement Secure-IC's portfolio. All the current and new customers will benefit from this acquisition as they will always retain top-notch security and performance. As of today, Secure-IC will now offer the largest portfolio of embedded security solutions to the market.

This acquisition will simplify development, accelerate time-to-market, and help device makers and OEMs to make products future-proof when it comes to security. All customers will be able to take advantage of the most advanced integrated security platform available today, including lifecycle management.

Secure-IC has been providing the market, for over a decade, with its protection technologies, namely the SecuryzrTM integrated Security Services Platform (iSSP). This enables its customers and partners to secure and manage their fleet of devices from the cloud and be provided with added-value security services, as well as compliance to standards.

“The combination of Secure-IC and Silex Insight is going to bring a unique high assurance security level to the market. Our mission is to provide our customers with solutions which perfectly fit their requirements, and offer outstanding quality, so that it is easy to implement right through to tape-out and beyond”, said Hassan Triqui, CEO of Secure-IC.

“By handing over our security business to Secure-IC, we are assured that the customers are in the best hands to help them design devices with the highest security standards. At the same time customers will be able to design solutions that are scalable and can be updated in the field”, said Michel Van Maercke, CEO of Silex Insight.

This marks the start of an exciting new era for embedded security solutions, creating a global leader, ready to set the standards for current and future challenges, such as the post-quantum cryptography revolution.

Secure-IC
With presence and customers across 5 continents, Secure-IC is the rising leader and the only global provider of end-to-end cybersecurity solutions for embedded systems and connected objects. Secure-IC provides Silicon-proven and cutting-edge protection technologies, integrated Secure Elements and security evaluation platforms to reach compliance with highest level of certification.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yucatan
jabourgier@yucatan.fr
+33-(0)1-53-63-27-27

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release

Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release

Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release

Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three

Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye